LIKMEZ Drug Patent Profile
✉ Email this page to a colleague
When do Likmez patents expire, and what generic alternatives are available?
Likmez is a drug marketed by Saptalis Pharms and is included in one NDA. There is one patent protecting this drug.
This drug has five patent family members in five countries.
The generic ingredient in LIKMEZ is metronidazole. There are eighteen drug master file entries for this compound. Seventy suppliers are listed for this compound. Additional details are available on the metronidazole profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Likmez
A generic version of LIKMEZ was approved as metronidazole by TEVA PHARMS USA on November 6th, 1984.
Summary for LIKMEZ
International Patents: | 5 |
US Patents: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for LIKMEZ |
What excipients (inactive ingredients) are in LIKMEZ? | LIKMEZ excipients list |
DailyMed Link: | LIKMEZ at DailyMed |
Pharmacology for LIKMEZ
Drug Class | Nitroimidazole Antimicrobial |
Anatomical Therapeutic Chemical (ATC) Classes for LIKMEZ
US Patents and Regulatory Information for LIKMEZ
LIKMEZ is protected by one US patents.
Patents protecting LIKMEZ
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Saptalis Pharms | LIKMEZ | metronidazole | SUSPENSION;ORAL | 216755-001 | Sep 22, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for LIKMEZ
See the table below for patents covering LIKMEZ around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Brazil | 112020014376 | composição farmacêutica oral, e, método para tratar uma infecção em um paciente. | ⤷ Try a Trial |
European Patent Office | 3768321 | FORMULATIONS ORALES DE MÉTRONIDAZOLE ET MÉTHODES DE TRAITEMENT D'UNE INFECTION FAISANT APPEL À CELLES-CI (ORAL FORMULATIONS OF METRONIDAZOLE AND METHODS OF TREATING AN INFECTION USING SAME) | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2019140516 | ⤷ Try a Trial | |
Mexico | 2020007494 | FORMULACIONES ORALES DE METRONIDAZOL Y METODOS DE TRATAMIENTO DE UNA INFECCION CON LAS MISMAS. (ORAL FORMULATIONS OF METRONIDAZOLE AND METHODS OF TREATING AN INFECTION USING SAME.) | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for LIKMEZ
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0328535 | 96C0021 | Belgium | ⤷ Try a Trial | PRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |